Search company, investor...

@it

crack.at.it

Founded Year

2000

Stage

Series A | Dead

About @it

Provider of a people awareness engine that enables visitors to a Web site to see how many other people are simultaneously visiting the site, and chat with each other. The company provides a people awareness engine that allows everyone on a particular Web site to see, identify, and chat with all other visitors of the site. The company's engine also enables visitors to a Web site to invite any other visitors to a public or private chat using text, and establish an online identity. The company's engine allows service providers to track the number of visitors to a particular site, offer online services to visitors, and configure interfaces and services according to visitor preferences. The company's engine allows Webmasters to monitor the activity of all visitors to their site.

Headquarters Location

Vainonkeskus Vainonkatu 26

Jyvaskyla, 40100,

Finland

358 5 0522 8736

Missing: @it's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: @it's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

@it Patents

@it has filed 1 patent.

The 3 most popular patent topics include:

  • Artificial intelligence
  • Industrial machine manufacturers
  • Natural language processing
patents chart

Application Date

Grant Date

Title

Related Topics

Status

6/5/2017

3/22/2022

Remote desktop, Serial buses, Computer buses, Microcontrollers, Network protocols

Grant

Application Date

6/5/2017

Grant Date

3/22/2022

Title

Related Topics

Remote desktop, Serial buses, Computer buses, Microcontrollers, Network protocols

Status

Grant

Latest @it News

Validation Parameters of Patient-Generated Data for Digitally Recorded Allergic Rhinitis Symptom and Medication Scores in the @IT.2020 Project: Exploratory Study

Jun 3, 2022

Background: Mobile health technologies enable allergists to monitor disease trends by collecting daily patient-reported outcomes of allergic rhinitis. To this end, patients with allergies are usually required to enter their symptoms and medication repetitively over long time periods, which may present a risk to data completeness and quality in the case of insufficient effort reporting. Completeness of patient’s recording is easily measured. In contrast, the intrinsic quality and accuracy of the data entered by the patients are more elusive. Objective: The aim of this study was to explore the association of adherence to digital symptom recording with a predefined set of parameters of the patient-generated symptom and medication scores and to identify parameters that may serve as proxy measure of the quality and reliability of the information recorded by the patient. Methods: The @IT.2020 project investigates the diagnostic synergy of mobile health and molecular allergology in patients with seasonal allergic rhinitis. In its pilot phase, 101 children with seasonal allergic rhinitis were recruited in Rome and instructed to record their symptoms, medication intake, and general conditions daily via a mobile app (AllergyMonitor) during the relevant pollen season. We measured adherence to daily recording as the percentage of days with data recording in the observation period. We examined the patient’s trajectories of 3 disease indices (Rhinoconjunctivitis Total Symptom Score [RTSS], Combined Symptom and Medication Score [CSMS], and Visual Analogue Scale [VAS]) as putative proxies of data quality with the following 4 parameters: (1) intravariation index, (2) percentage of zero values, (3) coefficient of variation, and (4) percentage of changes in trend. Lastly, we examined the relationship between adherence to recording and each of the 4 proxy measures. Results: Adherence to recording ranged from 20% (11/56) to 100% (56/56), with 64.4% (65/101) and 35.6% (36/101) of the patients’ values above (highly adherent patients) or below (low adherent patients) the threshold of 80%, respectively. The percentage of zero values, the coefficient of variation, and the intravariation index did not significantly change with the adherence to recording. By contrast, the proportion of changes in trend was significantly higher among highly adherent patients, independently from the analyzed score (RTSS, CSMS, and VAS). Conclusions: The percentage of changes in the trend of RTSS, CSMS, and VAS is a valuable candidate to validate the quality and accuracy of the data recorded by patients with allergic rhinitis during the pollen season. The performance of this parameter must be further investigated in real-life conditions before it can be recommended for routine use in apps and electronic diaries devoted to the management of patients with allergic rhinitis.

@it Frequently Asked Questions (FAQ)

  • When was @it founded?

    @it was founded in 2000.

  • Where is @it's headquarters?

    @it's headquarters is located at Vainonkeskus, Jyvaskyla.

  • What is @it's latest funding round?

    @it's latest funding round is Series A.

  • Who are the investors of @it?

    Investors of @it include Midinvest Management.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.